[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356477-105":59,"doc-detail-356477-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","complement-system-in-cancer-friend-or-foe-of-immunotherapy-review","Complement system in cancer: friend or foe of immunotherapy - Review","","The complement system, a core component of immune defense, can act in opposing ways in cancer by shaping both tumor suppression and tumor progression. Its activation pathways (classical, alternative, and lectin) drive opsonization and cell lysis, yet within the tumor microenvironment complement signaling may either enhance immune control or promote immune evasion and growth. Therapeutic modalities such as radiation and some chemotherapies can activate complement via immunogenic cell death and DAMP release, generating C3a and C5a that recruit antitumor cells. The same fragments can also induce immunosuppression by attracting Tregs and MDSCs, while tumors upregulate CD46, CD55, and CD59 to resist complement-mediated cytotoxicity. Complement inhibition, especially targeting C3aR and C5aR1, can synergize with immune checkpoint inhibitors to reverse complement-driven immunosuppression and improve T-cell–mediated rejection. Combining complement blockade with proimmunogenic therapies may further decouple beneficial complement activation from suppressive consequences, supporting tumor sensitization and overcoming resistance, though ongoing research is needed to optimize strategies and minimize immune escape.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/complement-system-in-cancer-friend-or-foe-of-immunotherapy-review/356477/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/complement-system-in-cancer-friend-or-foe-of-immunotherapy-review/356477.png","ImageObject",300,407,{"name":92,"@type":93},"Aurelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How does the complement system contribute to both tumor suppression and tumor progression?","Question",{"text":112,"@type":113},"Complement activation can enhance tumor control by promoting opsonization, antigen presentation, and cytotoxic T-cell responses. In the tumor microenvironment, it can also support progression by inducing epithelial-to-mesenchymal transitions, recruiting immunosuppressive cells, and sustaining chronic inflammation.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Why can complement activation improve immunotherapy effectiveness and also reduce it?",{"text":117,"@type":113},"Complement can synergize with immune checkpoint inhibitors, radiotherapy, and chemotherapy by strengthening antitumor immunity through recruitment and immune activation. At the same time, excessive or uncontrolled complement signaling may create a tolerogenic microenvironment that dampens therapeutic efficacy.",{"name":119,"@type":110,"acceptedAnswer":120},"What is the rationale for complement inhibition in cancer treatment?",{"text":121,"@type":113},"Targeting complement signaling—particularly via receptors such as C3aR and C5aR1—can reverse complement-driven immunosuppression and enhance T-cell–mediated tumor rejection. This approach may work synergistically with immune checkpoint inhibitors and proimmunogenic therapies like radiation or chemotherapy.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},356477,1790409017,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099514068365,"https://ap-avatar.wpscdn.com/avatar/10000253d8d9f28188e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1794309523707217728","Open access Review  \n Complement system in cancer: friend or foe of immunotherapy  \nHarendra Kumar Shah,1 Sai Prem  ,1 Xiaobo Wu,2 M Kathryn Liszewski,2 John P Atkinson,2 Abhay Kumar Singh  ,1,3 Vaishali Kapoor  1,4  \nTo cite: Shah HK, Prem S, Wu X, et al. Complement system in cancer: friend or foe of immunotherapy. Journal for ImmunoTherapy of Cancer 2026;14:e013290 . doi:10 . 1136/ jitc-2025-013290  \nAccepted 20 February 2026  \n© Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.  \n1Department of Radiation Oncology, Washington University in St Louis School of Medicine, St Louis, Missouri, USA 2Division of Rheumatology, Department of Medicine, Washington University in St Louis School of Medicine, St Louis, Missouri, USA 3MilliporeSigma St Louis, St Louis, Missouri, USA 4Siteman Cancer Center, St Louis, Missouri, USA  \nCorrespondence to  \nDr Vaishali Kapoor; [vkapoor@wustl.edu](vkapoor@wustl.edu)  \nABSTRACT  \nThe complement system, a key component of the immune response, plays a dual role in cancer, influencing both tumor suppression and progression. Its three activation pathways (classical, alternative, and lectin) initiate immune processes, including opsonization and cell lysis. Within the tumor microenvironment, however, complement activation can paradoxically support immune-mediated tumor control or contribute to immune evasion and tumor growth. Therapeutic interventions such as radiation and certain chemotherapies can trigger complement activation by inducing immunogenic cell death and the release of damage-associated molecular patterns. This activation leads to the generation of anaphylatoxins C3a and C5a, which recruit immune cells to the tumor site and promote antitumor immunity. However, these same fragments may also foster an immunosuppressive microenvironment by attracting regulatory T cells and myeloid-derived suppressor cells, thereby limiting the efficacy of immunotherapies. Additionally, tumor cells often upregulate membrane complement regulatory proteins, including CD46, CD55, and CD59, to escape complementmediated cytotoxicity and immune surveillance. Recent insights indicate that the complement system is a critical barrier to effective immunotherapy. Complement inhibition, particularly by targeting C3a receptor and C5a receptor 1, has been shown to synergize with immune checkpoint inhibitors (eg, anti-programmed cell death protein-1/programmed death-ligand 1), reversing complement-driven immunosuppression and enhancing T cell–mediated tumor rejection. Combining complement blockade with proimmunogenic therapies such as radiation or chemotherapy may further amplify these effects by uncoupling therapy-induced complement activation from its immunosuppressive consequences. Thus, the interplay between complement activation and cancer therapeutics presents a promising avenue for treatment innovations. Strategic modulation of complement, whether through genetic, pharmacologic, or antibody-based approaches, could sensitize tumors to immunotherapy and help overcome resistance mechanisms. Continued investigation into this crosstalk will be essential for designing effective combination strategies that maximize antitumor immunity while minimizing immune escape.  \nINTRODUCTION  \nThe complement system is a crucial part of the immune system, acting as a first line of defense against foreign pathogens through opsonization, phagocytosis, and cell lysis.1  \nIt is also involved in the removal of immune complexes, stressed cells, and apoptotic bodies.2 Studies have shown that complement activation may augment tumor cell lysis and decrease tumor growth. However, depending on the tumor microenvironment (TME), it can either protect from or favor tumorigenesis. 1 3 Complement activation enhances tumor cell clearance by promoting opsonization, activating dendritic cells (DCs), facilitating antigen presentation, and stimulating cytotoxic T ce","cbCaif5ullhEDJ6k","https://ap.wps.com/l/cbCaif5ullhEDJ6k","pdf",1742168,17,"English","# Abstract\n# Introduction\n# The Complement System and Its Regulation\n## Canonical activation pathways","[{\"question\":\"How does the complement system contribute to both tumor suppression and tumor progression?\",\"answer\":\"Complement activation can enhance tumor control by promoting opsonization, antigen presentation, and cytotoxic T-cell responses. In the tumor microenvironment, it can also support progression by inducing epithelial-to-mesenchymal transitions, recruiting immunosuppressive cells, and sustaining chronic inflammation.\"},{\"question\":\"Why can complement activation improve immunotherapy effectiveness and also reduce it?\",\"answer\":\"Complement can synergize with immune checkpoint inhibitors, radiotherapy, and chemotherapy by strengthening antitumor immunity through recruitment and immune activation. At the same time, excessive or uncontrolled complement signaling may create a tolerogenic microenvironment that dampens therapeutic efficacy.\"},{\"question\":\"What is the rationale for complement inhibition in cancer treatment?\",\"answer\":\"Targeting complement signaling—particularly via receptors such as C3aR and C5aR1—can reverse complement-driven immunosuppression and enhance T-cell–mediated tumor rejection. This approach may work synergistically with immune checkpoint inhibitors and proimmunogenic therapies like radiation or chemotherapy.\"}]","Complement system in cancer: friend or foe of immunotherapy - Review | PDF",1790125508,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ce72e07c17cb2afbd8c1dff61aa071cf.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fbc88f07a1b50122a58b09ea1cef5454.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ed1072dfeb1b56c1c5c04e676e2ae860.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c8038a7ed12cde85ec0e408e212e7f72.webp",980,1306]